Table 2.
Summary of incidence and case fatality rate by FIGO 2014 stage for ovarian and tubal cancer
|
FIGO 2014 stage |
Total | ||||||
|---|---|---|---|---|---|---|---|
| I | II | III | IV | Unable to stage | |||
| Ovarian and tubal cancers (WHO 2014 classification)* | |||||||
| No screening | |||||||
| Cases | 212 (20·9%) | 73 (7·2%) | 510 (50·2%) | 208 (20·5%) | 13 (1·3%) | 1016 | |
| Deaths | 20 (9·4%) | 24 (32·9%) | 391 (76·7%) | 174 (83·7%) | 10 (76·9%) | 609 (59·9%) | |
| MMS | |||||||
| Cases | 155 (29·7%) | 42 (8·0%) | 242 (46·4%) | 78 (14·9%) | 5 (1·0%) | 522 | |
| Deaths | 23 (14·8%) | 16 (38·1%) | 190 (78·5%) | 62 (79·5%) | 4 (80·0%) | 291 (55·7%) | |
| USS | |||||||
| Cases | 121 (23·4%) | 36 (7·0%) | 253 (48·9%) | 105 (20·3%) | 2 (0·4%) | 517 | |
| Deaths | 8 (6·6%) | 6 (16·7%) | 188 (74·3%) | 88 (83·8%) | 2 (100·0%) | 290 (56·1%) | |
| Between group differences in cases compared with no screening at 9·5 years after end of screening† | |||||||
| MMS | 47·2% (19·7 to 81·1) | 15·9% (−20·7 to 69·4) | −4·4% (−18·0 to 11·4) | −24·5% (−41·8 to −2·0) | .. | .. | |
| USS | 17·0% (−6·4 to 46·2) | 1·1% (−32·2 to 50·6) | 1·7% (−12·6 to 18·2) | 3·4% (−18·2 to 30·8) | .. | .. | |
| Invasive epithelial ovarian and tubal cancers (WHO 2014 classification)* | |||||||
| No screening | |||||||
| Cases | 116 (12·8%) | 69 (7·6%) | 501 (55·3%) | 208 (23·0%) | 12 (1·3%) | 906 | |
| Deaths | 18 (15·5%) | 24 (34·8%) | 391 (78·0%) | 174 (83·7%) | 10 (83·3%) | 617 (68·1%) | |
| MMS | |||||||
| Cases | 91 (20·1%) | 41 (9·1%) | 237 (52·4%) | 78 (17·3%) | 5 (1·1%) | 452 | |
| Deaths | 22 (24·2%) | 16 (39·0%) | 190 (80·2%) | 62 (79·5%) | 4 (80·0%) | 294 (65·0%) | |
| USS | |||||||
| Cases | 55 (12·4%) | 35 (7·9%) | 249 (56·0%) | 104 (23·4%) | 2 (0·4%) | 445 | |
| Deaths | 7 (12·7%) | 6 (17·1%) | 186 (74·7%) | 87 (83·7%) | 2 (100·0%) | 288 (64·7%) | |
| Between group differences in cases compared with no screening at 9·5 years after end of screening† | |||||||
| MMS | 52·2% (16·8 to 98·4) | 15·8% (−19·4 to 66·4) | −4·8% (−18·3 to 10·9) | −23·7% (−40·7 to −1·7) | .. | .. | |
| USS | −8·0% (−32·7 to 25·7) | −5·2% (−35·8 to 39·9) | 0·5% (−13·6 to 16·8) | −0·8% (−21·3 to 25·1) | .. | .. | |
Data for cases are n (%); data for deaths are n (case fatality rate for stage); data for between group differences in cases are percentage (95% CI). FIGO=Federation of Gynecology and Obstetrics. MMS=multimodal screening. USS=ultrasound screening.
*
Includes cases previously designated as primary peritoneal cancer as per WHO 2003 classification.
†
Between group differences from a poisson model with length of analysis time as exposure variable; percentage difference taken from the incidence rate ratio, where percentage difference equals incidence rate ratio minus 1 multiplied by 100%.